Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZT002 in Healthy Participants
NCT06423872Phase 1Completed
- Sponsor
- QL Biopharm
- Start
- Jun 2023
- Primary completion
- Oct 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing ZT002 with Placebo (2 arms). Primary endpoints: Treatment Emergent Adverse Events up to 50 days and Serious Adverse Events up to 50 days. Started Jun 2023; status: completed.
02
Drugs
zovaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06423872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06423872.